Show simple item record

dc.contributor.authorCourtois, Sarah
dc.contributor.authorLuxán Delgado, Beatriz de
dc.contributor.authorPenin Peyta, Laure
dc.contributor.authorRoyo García, Alba
dc.contributor.authorPareja Alonso, Beatriz
dc.contributor.authorJagust, Petra
dc.contributor.authorAlcalá, Sonia
dc.contributor.authorRubiolo Gaytán, Juan Andrés
dc.contributor.authorSánchez Piñón, Laura Elena
dc.contributor.authorSainz Anding, Bruno
dc.contributor.authorHeeschen, Christopher
dc.contributor.authorSancho, Patricia
dc.date.accessioned2021-02-12T11:38:42Z
dc.date.available2021-02-12T11:38:42Z
dc.date.issued2021
dc.identifier.citationCancers 2021, 13(4), 698; https://doi.org/10.3390/cancers13040698
dc.identifier.urihttp://hdl.handle.net/10347/24423
dc.description.abstractPancreatic ductal adenocarcinoma (PDAC) is one of the deadliest tumors, partly due to its intrinsic aggressiveness, metastatic potential, and chemoresistance of the contained cancer stem cells (CSCs). Pancreatic CSCs strongly rely on mitochondrial metabolism to maintain their stemness, therefore representing a putative target for their elimination. Since mitochondrial homeostasis depends on the tightly controlled balance between fusion and fission processes, namely mitochondrial dynamics, we aim to study this mechanism in the context of stemness. In human PDAC tissues, the mitochondrial fission gene DNM1L (DRP1) was overexpressed and positively correlated with the stemness signature. Moreover, we observe that primary human CSCs display smaller mitochondria and a higher DRP1/MFN2 expression ratio, indicating the activation of the mitochondrial fission. Interestingly, treatment with the DRP1 inhibitor mDivi-1 induced dose-dependent apoptosis, especially in CD133+ CSCs, due to the accumulation of dysfunctional mitochondria and the subsequent energy crisis in this subpopulation. Mechanistically, mDivi-1 inhibited stemness-related features, such as self-renewal, tumorigenicity, and invasiveness and chemosensitized the cells to the cytotoxic effects of Gemcitabine. In summary, mitochondrial fission is an essential process for pancreatic CSCs and represents an attractive target for designing novel multimodal treatments that will more efficiently eliminate cells with high tumorigenic potential
dc.description.sponsorshipThis research was funded by the Pancreatic Cancer Research Fund, 2015 Award Round (P.S., C.H.); the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 602783 (CAM-PaC) (C.H.), the Worldwide Cancer Research Charity together with Fundación Científica Asociación Española contra el Cáncer (FCAECC) (19-0250) (P.S.); A Fero Foundation grant and a Coordinated grant (GC16173694BARB) from the Fundación Asociación Española Contra el Cáncer (AECC) (B.S.J.); and the Instituto de Salud Carlos III through the Miguel Servet Program (CP16/00121) and Fondo de Investigaciones Sanitarias (PI17/00082) (both co-financed by European funds (FSE: “El FSE invierte en tu futuro” and FEDER: “Una manera de hacer Europa,” respectively) (P.S.)
dc.language.isoeng
dc.publisherMDPI
dc.relationinfo:eu-repo/grantAgreement/EC/FP7/602783
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectMitochondria
dc.subjectMitochondrial dynamics
dc.subjectMitochondrial fission
dc.subjectCancer stem cells
dc.subjectCD133
dc.subjectDRP1
dc.subjectEnergy crisis
dc.subjectPDAC
dc.subjectPancreatic cancer
dc.titleInhibition of Mitochondrial Dynamics Preferentially Targets Pancreatic Cancer Cells with Enhanced Tumorigenic and Invasive Potential
dc.typeinfo:eu-repo/semantics/article
dc.identifier.DOI10.3390/cancers13040698
dc.relation.publisherversionhttps://doi.org/10.3390/cancers13040698
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.e-issn2072-6694
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Zooloxía, Xenética e Antropoloxía Física
dc.description.peerreviewedSI


Files in this item

application/pdf
Name: 2021_cancers_courtois_inhibition.pdf
Size: 2.065 Mb
Format: PDF


Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Except where otherwise noted, this item's license is described as  © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)





Harvesters:Useful links:
Universidade de Santiago de Compostela | Teléfonos: +34 881 811 000 e +34 982 820 000 | Contact Us | Send Feedback